Skip to main content

Advertisement

SpringerLink
Log in

Angiogenesis inhibition: the next frontier in multimodal therapy for glioblastoma multiforme

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62

    Article  CAS  Google Scholar 

  2. Yuan F et al. (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765–14770

    Article  CAS  Google Scholar 

  3. Segers J et al. (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 244: 129–135

    Article  CAS  Google Scholar 

  4. Tong RT et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731–3736

    Article  CAS  Google Scholar 

  5. Winkler F et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553–563

    CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rohit R Sharma and Ralph R Weichselbaum.

Author information

Authors and Affiliations

  1. RR Sharma is a Fellow in Surgical Oncology, and RR Weichselbaum is the Daniel K Ludwig Professor and Chairman of Radiation Oncology and Head of The Ludwig Center for Metastasis Research, at the University of Chicago, Chicago, IL, USA.,

    Rohit R Sharma & Ralph R Weichselbaum

Authors
  1. Rohit R Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph R Weichselbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralph R Weichselbaum.

Ethics declarations

Competing interests

RR Sharma declared he has no competing interests. RR Weichselbaum has declared stock, consulting fees and research agreement with GenVec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, R., Weichselbaum, R. Angiogenesis inhibition: the next frontier in multimodal therapy for glioblastoma multiforme. Nat Rev Clin Oncol 4, 454–455 (2007). https://doi.org/10.1038/ncponc0879

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0879

  • Springer Nature Limited

Search

Navigation